WHO panel advises on governance of genome editing
Interviewee/Contributor
Victoria English
Organisation
MedNous
Gene therapy
VectorY Therapeutics targets misfolded proteins
Interviewee/Contributor
Alexander Vos and Sander van Deventer
Organisation
VectorY Therapeutics BV
A new paradigm for gene therapy
Interviewee/Contributor
Peter Marks
Organisation
US Food and Drug Administration
Addressing the challenges of gene therapy medicinal products
Interviewee/Contributor
Paula Salmikangas and Björn Carlsson
Organisation
NDA Group
Purespring to develop gene therapies for the kidney
Interviewee/Contributor
Richard Francis
Organisation
Purespring Therapeutics Ltd
Integrated product development for ATMPs
Interviewee/Contributor
Claes Buxfeldt and Paula Salmikangas
Organisation
NDA Advisory Services Ltd
A new paradigm for cancer therapy emerges
Interviewee/Contributor
Victoria English
Organisation
MedNous
The role of base and prime editing in therapeutics
Interviewee/Contributor
Jonathan Frampton
Organisation
Horizon Discovery Group Plc
Gene-edited therapies produce first clinical data
Interviewee/Contributor
Janet Lambert
Organisation
Alliance for Regenerative Medicine
Gene and cell therapy as a new pillar of medicine
Interviewee/Contributor
Miguel Forte
Organisation
Bone Therapeutics SA